SLC5A2 and type 2 diabetes mellitus: A real-world study revealed that, irrespective of age, sex, prior-existing cardiovascular disease, or type of SGLT2 inhibitor used, patients with type 2 diabetes who were initiated on SGLT2 inhibitors exhibited a lower incidence of sepsis risk (47).